Literature DB >> 22784019

OnabotulinumtoxinA (BOTOX®): a guide to its use in preventing headaches in adults with chronic migraine.

Katherine A Lyseng-Williamson1, James E Frampton.   

Abstract

Intramuscular onabotulinumtoxinA (onaBoNTA; BOTOX®) is indicated for headache prophylaxis in adults with chronic migraine. According to pooled results from two large trials, treatment with up to five cycles of onaBoNTA (155-195 units/cycle) at 12-week intervals was effective in reducing headache symptoms, decreasing headache-related disability and improving health-related quality of life in patients with chronic migraine. OnaBoNTA was generally well tolerated in these trials, with an adverse event profile that was consistent with that of the neurotoxin when injected into head and neck muscles.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22784019     DOI： 10.2165/11208930-000000000-00000

Source DB:  PubMed          Journal:  CNS Drugs        ISSN： 1172-7047            Impact factor:   5.749


  23 in total

1.  A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine.

Authors:  Roger K Cady; Curtis P Schreiber; John A H Porter; Andrew M Blumenfeld; Kathleen U Farmer
Journal:  Headache       Date:  2010-11-10       Impact factor: 5.887

2.  OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.

Authors:  S K Aurora; D W Dodick; C C Turkel; R E DeGryse; S D Silberstein; R B Lipton; H C Diener; M F Brin
Journal:  Cephalalgia       Date:  2010-03-17       Impact factor: 6.292

3.  OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.

Authors:  Sheena K Aurora; Paul Winner; Marshall C Freeman; Egilius L Spierings; Jessica O Heiring; Ronald E DeGryse; Amanda M VanDenburgh; Marissa E Nolan; Catherine C Turkel
Journal:  Headache       Date:  2011-08-29       Impact factor: 5.887

Review 4.  Migraine with aura: conventional and non-conventional treatments.

Authors:  Giovanni D'Andrea; Davide Colavito; Maurizio Dalle Carbonare; Alberta Leon
Journal:  Neurol Sci       Date:  2011-05       Impact factor: 3.307

5.  New appendix criteria open for a broader concept of chronic migraine.

Authors:  J Olesen; M-G Bousser; H-C Diener; D Dodick; M First; P J Goadsby; H Göbel; M J A Lainez; J W Lance; R B Lipton; G Nappi; F Sakai; J Schoenen; S D Silberstein; T J Steiner
Journal:  Cephalalgia       Date:  2006-06       Impact factor: 6.292

Review 6.  OnabotulinumtoxinA (BOTOX®): a review of its use in the prophylaxis of headaches in adults with chronic migraine.

Authors:  James E Frampton
Journal:  Drugs       Date:  2012-04-16       Impact factor: 9.546

7.  EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force.

Authors:  S Evers; J Afra; A Frese; P J Goadsby; M Linde; A May; P S Sándor
Journal:  Eur J Neurol       Date:  2009-09       Impact factor: 6.089

8.  A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study.

Authors:  Ninan T Mathew; Sayyed Farhan A Jaffri
Journal:  Headache       Date:  2009 Nov-Dec       Impact factor: 5.887

Review 9.  Clinical relevance of botulinum toxin immunogenicity.

Authors:  Reiner Benecke
Journal:  BioDrugs       Date:  2012-04-01       Impact factor: 5.807

10.  Increased levels of SV2A botulinum neurotoxin receptor in clinical sensory disorders and functional effects of botulinum toxins A and E in cultured human sensory neurons.

Authors:  Yiangos Yiangou; Uma Anand; William R Otto; Marco Sinisi; Michael Fox; Rolfe Birch; Keith A Foster; Gaurav Mukerji; Ayesha Akbar; Sanjiv K Agarwal; Praveen Anand
Journal:  J Pain Res       Date:  2011-10-18       Impact factor: 3.133
View more
  2 in total

1.  Advances in drug development for acute migraine.

Authors:  Ryan J Cady; Candace L Shade; Roger K Cady
Journal:  Drugs       Date:  2012-12-03       Impact factor: 9.546

2.  Irritable bowel syndrome and migraine: bystanders or partners?

Authors:  Full-Young Chang; Ching-Liang Lu
Journal:  J Neurogastroenterol Motil       Date:  2013-07-08       Impact factor: 4.924
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.